Fortis Capital Advisors, LLC Cassava Sciences Inc Transaction History
Fortis Capital Advisors, LLC
- $631 Billion
- Q3 2025
A detailed history of Fortis Capital Advisors, LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Fortis Capital Advisors, LLC holds 12,563 shares of SAVA stock, worth $34,673. This represents 0.01% of its overall portfolio holdings.
Number of Shares
12,563Holding current value
$34,673% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding SAVA
# of Institutions
135Shares Held
15.9MCall Options Held
1.26MPut Options Held
791K-
Black Rock Inc. New York, NY3.22MShares$8.89 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.29MShares$6.32 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.06MShares$5.69 Million0.01% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny962KShares$2.65 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY565KShares$1.56 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $111M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...